ApTOLL, a new therapeutic aptamer for cytoprotection and (re)myelination after Multiple Sclerosis.
Beatriz Fernández‐Gómez, Miguel Marchena, David Piñeiro, Paula Gómez‐Martín, Estefanía Sánchez-Jiménez, Yolanda Laó, Gloria Valencia, Sonia Nocera, Rocío Benítez‐Fernández, Ana María Castaño-León, Alfonso Lagares, Macarena Hernández‐Jiménez, Fernando de Castro
ApTOLL, an aptamer targeting TLR4, shows immunomodulatory and remyelinating effects in MS models and cell cultures.
British Journal of Pharmacology · May 14, 2024Peer-reviewedNeuroscience